Exploration of the Regulatory Mechanism of Inflammasomes in Liver Fibrosis and New Therapeutic Targets

Jinqing Li; Jia Li

doi:10.54097/y8qmqj45

Authors

Jinqing Li
Jia Li

DOI:

https://doi.org/10.54097/y8qmqj45

Keywords:

Inflammasome Regulation Mechanism, Liver Fibrosis, Animal Models, Gene Editing Technology

Abstract

This article explores optimization strategies for the regulation mechanism of inflammasomes, promoting the development of liver fibrosis treatment. By constructing more accurate animal models and utilizing gene editing technology to simulate the characteristics of human liver fibrosis; Emphasize interdisciplinary collaboration and accelerate the translation of basic research results into clinical applications. Successfully constructed a high-precision animal model, providing a reliable platform for further exploration of the regulatory mechanism of inflammasomes; Interdisciplinary collaboration promotes the development of new therapies. Optimization strategies for the regulation mechanism of inflammasomes, including the construction of precise animal models and interdisciplinary cooperation, are expected to provide safer and more effective treatment options for patients with liver fibrosis.

Downloads

Download data is not yet available.

References

[1] World Health Organization. (2021). Global hepatitis report 2021. Geneva: World Health Organization.

[2] Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). Burden of liver diseases in the world. Journal of Hepatology, 70(1), 151-171.

[3] Martinon, F., et al. (2009). The inflammasomes: guardians of the body. Annual Review of Immunology, 27, 229-265.

[4] Schroder, K., & Tschopp, J. (2010). The inflammasomes. Cell, 140(6), 821-832.

[5] Wree, A., et al. (2014). NLRP3 inflammasome activation is required for fibrosis development in NAFLD. Journal of Molecular Medicine, 92(10), 1069-1082.

[6] Szabo, G., & Petrasek, J. (2015). Inflammasome activation and function in liver disease. Nature Reviews Gastroenterology & Hepatology, 12(7), 387-400.

[7] Koyama, Y., & Brenner, D. A. (2017). Liver inflammation and fibrosis. Journal of Clinical Investigation, 127(1), 55-64.

[8] Inzaugarat, M. E., et al. (2019). NLR family pyrin domain-containing 3 inflammasome activation in hepatic stellate cells induces liver fibrosis in mice. Hepatology, 69(2), 845-859.

[9] Tacke, F., & Trautwein, C. (2015). Mechanisms of liver fibrosis resolution. Journal of Hepatology, 63(4), 1038-1049.

[10] Coll, R. C., et al. (2019). MCC950 directly targets the NLRP3 ATPase activity for inflammasome inhibition. Nature Chemical Biology, 15(6), 556-559.

[11] Loomba, R., et al. (2021). Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell, 184(10), 2537-2564.

[12] Wang, S., et al. (2020). CRISPR/Cas9-based generation of knockdown mice by intronic insertion of artificial microRNA using longer single-stranded DNA. Scientific Reports, 10(1), 1-12.

[13] Mullard, A. (2021). Multidisciplinary collaboration in drug discovery. Nature Reviews Drug Discovery, 20(5), 333-335.

[14] Angeli, P., et al. (2022). Adaptive clinical trial design in hepatology: opportunities and challenges. Journal of Hepatology, 76(4), 742-754.